Communiqués Virpax Pharmaceuticals, Inc.

Actions

VRPX

US9282512063

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
0,7501 ^USD	-6,30 %		+7,16 %	-76,57 %

22/05	VIRPAX PHARMACEUTICALS, INC. : Maxim n'est plus acheteur	ZM
15/05	Virpax fixe le prix de son offre publique d'actions et de bons de souscription ; les actions chutent	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Virpax Pharmaceuticals to Present at 2024 BIO International Convention	30/05	AQ
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention	29/05	BU
Virpax Announces Pricing of $2.25 Million Public Offering	15/05	BU
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments	13/05	BU
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur	01/05	AQ
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™	30/04	BU
Virpax Pharmaceuticals Reports 2023 Year-End Results	26/03	BU
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price	28/02	AQ
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price	27/02	BU
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.	27/02	BU
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research	07/02	BU
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting	29/12	BU
Virpax Pharmaceuticals : Failure to Satisfy Listing Rule - Form 8-K	13/12	PU
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing	20/11	AQ
Virpax Pharmaceuticals Announces Leadership Transition	20/11	AQ
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing	17/11	BU
Virpax Pharmaceuticals Announces Leadership Transition	17/11	BU
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments	15/11	BU
Virpax Pharmaceuticals Announces that Envelta Remains on Track for Trial in Humans Following FDA Review	01/11	AQ
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review	31/10/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Virpax Pharmaceuticals, Inc.

Actions

VRPX

US9282512063

Communiqués

Filtres